Home / FINANCE / Markets Insider / Gala Pharmaceuticals Sees 2018 as Breakthrough Year for Company

Gala Pharmaceuticals Sees 2018 as Breakthrough Year for Company

ANAHEIM, Calif., Jan. 21, 2018 (GLOBE NEWSWIRE) — Gala Pharmaceuticals Inc. (GPI) (OTCBB:GLPH) currently announced that it is focusing on pivotal 2018 goals to expostulate success and build long-term shareholder value.

Gala Pharmaceuticals, in 2017, had streamlined a business model, did investigate and growth of pivotal plant species, cloning technologies and strengthened of a government team, all of that laid a substructure for 2018.

Gala Pharmaceuticals believes a following goals, if achieved, will concede a association to consistently grow a marketplace share in high margin, high distinction marketplace segments, so solidifying a company’s position as one of a many innovative companies in a marketplace, that should eventually boost shareholder value:

Goal #1:  Breeding, Tissue Culture and Cloning and High Throughput Testing:  GPI is focusing on a growth of innovative tact and informative collection for flourishing crops, vegetables and other high value plant species. The association is looking brazen to building high throughput screening technologies for chemical, plant, soil, and glass combination research that will concede test growth for pivotal compositional traits and produce peculiarity services to several business in rural industry.

Goal #2:  GPI Genetic Fingerprinting

GPI is also focusing on providing genetic “fingerprinting� and “sequencing� of several stand class in 2018. In doing so, it will be means to rise and store genetic fingerprint information into a disdainful database.  GPI business will afterwards have disdainful entrance to genetic fingerprint information that can be used for predictive tact applications and for safeguarding egghead skill (IP).

Goal #3:  Drug Formulations

The association is laying a grounds to concentration on drug plan processes.  The association is awaiting to produce slip for a growth of entirely Good Manufacturing Practices c(GMP), and prolongation of Active Pharmaceutical Ingredients (API) for use in clinical trials compulsory to support a reserve and efficiency of intensity drugs for a treatments of several medical conditions. 

It is believed that a investments done final year, with a concentration on building a genomics technologies as good as a plant cloning techniques, will infer to be dual of a biggest factors differentiating us from our competitors in a cultivation industry.  “I am intensely vehement about a destiny during Gala Pharmaceuticals, commencement with a expectancy to grasp a 3 initial goals only mentioned,� pronounced Gala Pharmaceuticals CEO, Maqsood Rehman. 

Gala Pharmaceuticals is looking brazen to heading a growth of innovative collection to urge produce and peculiarity for several plant class this year and a association believes it has a right organisation in place to safeguard success.  Throughout a march of a year. The association will continue to produce quarterly swell reports so that shareholders might magnitude company’s opening opposite a objectives set out in prior shareholder communications. This clarity should bleed serve certainty in company’s business indication and trust in a Company.

Dr. Maqsood Rehman
Chief Executive Officer
Gala Pharmaceuticals Inc.

About Gala Pharmaceuticals, Inc.

Gala Pharmaceuticals, Inc. (OTCBB:GLPH) is a publicly-traded startup growth association specializing in a biotech industry. Gala Pharmaceutical’s veteran services organisation provides operational services and technologies that expostulate efficiencies in a rural market.  Gala Pharmaceuticals has industry-leading imagination assisting companies make a many of their intensity in an rising market. 

Forward-looking Statements

Certain matters discussed in this press recover might enclose statements, estimates and projections that engage risks and uncertainties in Gala Pharmaceuticals Inc.’s business that might means tangible formula to differ materially from those expected by a statements done herein. Such statements, estimates and projections consecrate forward-looking statements within a definition of a sovereign bonds laws. Gala Pharmaceuticals Inc. undertakes no requirement to publicly refurbish or correct any forward-looking statements, either since of new information, destiny events or otherwise. The target of this information is cautioned not to place undue faith on forward-looking statements. No representations or warranties are done as to a correctness of such forward-looking statements or either any of a projections enclosed herein will be realized.

Investor/Media Contact:      
Bill Miller, Investor Relations
Phone: 844-565-5665             
bmiller@irpartnersinc.com     

Company Contact:
Maqsood Rehman
Phone: 657-215-5742
maqsood@galapharmaceuticals.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*

x

Check Also

Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia

- Investment supports flourishing direct for biopharmaceutical manufacturing – Builds capabilities with dual new prolongation and ...